Comparative study of the efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib versus methotrexate for disease-modifying antirheumatic drug-na ïve patients with rheumatoid arthritis.

In conclusion, tofacitinib, baricitinib, upadacitinib, and filgotinib were effective treatment options for DMARD-naïve RA patients, suggesting a difference in efficacy and safety among the different JAK inhibitors. PMID: 32970188 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32970188?dopt=Abstract

Source: Zeitschrift fur Rheumatologie - September 23, 2020 Category: Rheumatology Authors: Sung YK, Lee YH Tags: Z Rheumatol Source Type: research